Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 16,218 as of Tuesday, Feb. 25, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,600 issues advancing vs. 1,298 declining with 186 unchanged. The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.2%. Top gainers within the sector include InterMune ( ITMN), up 159.0%, Grifols ( GRFS), up 3.0% and Boston Scientific ( BSX), up 2.2%. On the negative front, top decliners within the sector include Humana ( HUM), down 1.9%, and UnitedHealth Group ( UNH), down 0.8%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Vertex Pharmaceuticals is up $1.73 (2.1%) to $85.68 on light volume. Thus far, 496,122 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $83.57-$85.98 after having opened the day at $84.21 as compared to the previous trading day's close of $83.95. Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $20.0 billion and is part of the drugs industry. Shares are up 13.0% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.